Listed by the USPTO as BUTTICE, AUDREY L
Tech Center 1600 • Art Units: 1641 1644 1647 1658 1683
This examiner grants 47% of resolved cases
Audrey L. Buttice has an allowance rate of 46.6% based on 146 resolved cases in Tech Center 1600. For applications in Art Unit 1641, the median days to allowance is 1268, which suggests a more challenging and time-consuming prosecution environment. These statistics are important for applicants to consider when evaluating the risks and timelines associated with their filings.
The interview lift of 26.0% is a notable figure, indicating that interviews are associated with a substantial increase in the likelihood of success over the 46.6% baseline. This suggests that direct engagement with the examiner is a critical tactical tool for overcoming rejections. Her top applicants include academic and research institutions such as Northwestern University and the Board of Regents of the University of Texas System.
Firms like Norton Rose Fulbright US LLP, pH IP Law, and WOLF GREENFIELD & SACKS, P.C. are among the primary representatives in her records. The 1268-day median and 26.0% lift provide a comprehensive view of the prosecution landscape in Tech Center 1600. Practitioners should utilize these metrics to adjust their strategies and manage expectations for cases in Art Unit 1641.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17774821 | COMBINATION OF A T CELL THERAPY AND (S)-3-[4-(4-MORPHOLIN-4-YLMETHYL-BENZYLOXY)-L-OXO-L,3-DIHYDRO-ISOINDOL-2-YL]-PIPERIDINE-2,6-DIONE | Final Rejection | Juno Therapeutics, Inc. |
| 18249057 | USE OF REELIN FOR TREATING CARDIAC DISEASES | Final Rejection | Northwestern University |
| 16951638 | METHOD OF USING CHECKPOINT KINASE INHIBITOR THERAPY TO MODULATE ANTI-TUMORAL RESPONSE AGAINST CANCER AND SENSITIZE GLIOMAS TO IMMUNOTHERAPY | Final Rejection | NORTHWESTERN UNIVERSITY |
| 18040586 | METHODS AND COMPOSITIONS FOR PANCREATIC CANCER EVALUATION AND TREATMENT | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18006652 | ENGINEERED T CELLS AND TUMOR-INFILTRATING LYMPHOCYTES TO INCREASE TUMOR KILLING | Non-Final OA | Board of Regents, The University of Texas System |
| 18259348 | GFRALPHA1-CONTAINING NEURITE OUTGROWTH PROMOTER AND PHARMACEUTICAL COMPOSITION FOR INDUCING NERVE REGENERATION | Non-Final OA | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY |
| 18245281 | CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS | Final Rejection | Baylor College of Medicine |
| 18266848 | CONDITIONALLY BISPECIFIC BINDING PROTEINS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 16754400 | METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES | Final Rejection | Actinium Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy46.6% of resolved applications examined by Audrey L Buttice were allowed (146 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +26.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Audrey L Buttice took 1,268 days on average from filing to allowance.
Audrey L Buttice examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
